Jones Trading initiating coverage on EyePoint Pharmaceuticals with a Buy rating and a $26 price target is a positive signal for the company. This recommendation suggests that the analyst believes the stock has significant upside potential, which could lead to increased investor interest and a short-term increase in the stock price.